Yogesh Jeelall
@yogeshjeelall.bsky.social
MD PhD, Haematology Trainee and Adjunct Research Fellow, Medical School, University of Western Australia interested in #Haematology #Genomics #ClonalEvolution #DataScience #Immunology
Reposted by Yogesh Jeelall
a thoughtful @bloodjournal.bsky.social article on recent negative Phase III studies in higher-risk MDS
ashpublications.org/blood/articl...
ashpublications.org/blood/articl...
November 14, 2025 at 1:27 AM
a thoughtful @bloodjournal.bsky.social article on recent negative Phase III studies in higher-risk MDS
ashpublications.org/blood/articl...
ashpublications.org/blood/articl...
Reposted by Yogesh Jeelall
excellent article in @bloodjournals.hematology.org on the challenges of incorporating novel therapies into the routine management of ALL!
ashpublications.org/bloodadvance...
ashpublications.org/bloodadvance...
October 21, 2025 at 12:15 PM
excellent article in @bloodjournals.hematology.org on the challenges of incorporating novel therapies into the routine management of ALL!
ashpublications.org/bloodadvance...
ashpublications.org/bloodadvance...
Reposted by Yogesh Jeelall
At 7 years old, Emily became the first child in the world to receive CAR T-cell therapy. After three relapses and being sent to hospice, Emily got a second chance at life with this treatment. Help protect access to life-saving treatments: https://ow.ly/rXY150X5Tso
#Fight4Hematology #HemeSky
#Fight4Hematology #HemeSky
October 10, 2025 at 2:01 PM
At 7 years old, Emily became the first child in the world to receive CAR T-cell therapy. After three relapses and being sent to hospice, Emily got a second chance at life with this treatment. Help protect access to life-saving treatments: https://ow.ly/rXY150X5Tso
#Fight4Hematology #HemeSky
#Fight4Hematology #HemeSky
Reposted by Yogesh Jeelall
WiLing Wednesday's Webinars are back! Join us for updates on various MCL topics presented by global experts, starting Oct 29 through to Nov 19.
Register on our website : womeninlymphoma.org/webinars
First session on Oct 29 : us06web.zoom.us/webinar/regi...
Register on our website : womeninlymphoma.org/webinars
First session on Oct 29 : us06web.zoom.us/webinar/regi...
September 23, 2025 at 11:31 PM
WiLing Wednesday's Webinars are back! Join us for updates on various MCL topics presented by global experts, starting Oct 29 through to Nov 19.
Register on our website : womeninlymphoma.org/webinars
First session on Oct 29 : us06web.zoom.us/webinar/regi...
Register on our website : womeninlymphoma.org/webinars
First session on Oct 29 : us06web.zoom.us/webinar/regi...
Reposted by Yogesh Jeelall
📢 Happening this week!
Join us on Friday 1 August as we explore key challenges and innovative approaches to improving immunoglobulin use.
View the program and register now for the OPTIMAL CRE Inaugural Open Meeting in Melbourne or online:
👉 OPTIMALCRE2025.eventbrite.com.au
Join us on Friday 1 August as we explore key challenges and innovative approaches to improving immunoglobulin use.
View the program and register now for the OPTIMAL CRE Inaugural Open Meeting in Melbourne or online:
👉 OPTIMALCRE2025.eventbrite.com.au
July 28, 2025 at 6:54 AM
📢 Happening this week!
Join us on Friday 1 August as we explore key challenges and innovative approaches to improving immunoglobulin use.
View the program and register now for the OPTIMAL CRE Inaugural Open Meeting in Melbourne or online:
👉 OPTIMALCRE2025.eventbrite.com.au
Join us on Friday 1 August as we explore key challenges and innovative approaches to improving immunoglobulin use.
View the program and register now for the OPTIMAL CRE Inaugural Open Meeting in Melbourne or online:
👉 OPTIMALCRE2025.eventbrite.com.au
Reposted by Yogesh Jeelall
July 23, 2025 at 12:01 PM
Reposted by Yogesh Jeelall
The Capstan Therapeutics team is exceptional. This is just the beginning of transforming the delivery of CAR T cell immunotherapies www.science.org/doi/10.1126/...
In vivo CAR T cell generation to treat cancer and autoimmune disease
Chimeric antigen receptor (CAR) T cell therapies have transformed treatment of B cell malignancies. However, their broader application is limited by complex manufacturing processes and the necessity f...
www.science.org
June 30, 2025 at 12:42 PM
The Capstan Therapeutics team is exceptional. This is just the beginning of transforming the delivery of CAR T cell immunotherapies www.science.org/doi/10.1126/...
Reposted by Yogesh Jeelall
New paper in @bloodjournal.bsky.social reporting a score incorporating IPSS-M, EPO level, transfusion dependence to predict ESA response in LR-MDS
ashpublications.org/blood/articl...
ashpublications.org/blood/articl...
June 30, 2025 at 1:23 PM
New paper in @bloodjournal.bsky.social reporting a score incorporating IPSS-M, EPO level, transfusion dependence to predict ESA response in LR-MDS
ashpublications.org/blood/articl...
ashpublications.org/blood/articl...
Reposted by Yogesh Jeelall
This study is remarkable in that it highlights, to our knowledge, for the first time, the importance of CD19.CAR+ EVs measured in the CAR T products vs in the peripheral blood of patients after infusion. buff.ly/UZCuwbq #hemesky
June 30, 2025 at 5:05 PM
This study is remarkable in that it highlights, to our knowledge, for the first time, the importance of CD19.CAR+ EVs measured in the CAR T products vs in the peripheral blood of patients after infusion. buff.ly/UZCuwbq #hemesky
Reposted by Yogesh Jeelall
The full manuscript describing outcomes of 7 days Aza + 7 days Ven in newly diagnosed AML is out!
-72% composite CR rate
-mOS 11.2 months
www.nature.com/articles/s41...
-72% composite CR rate
-mOS 11.2 months
www.nature.com/articles/s41...
April 22, 2025 at 2:06 AM
The full manuscript describing outcomes of 7 days Aza + 7 days Ven in newly diagnosed AML is out!
-72% composite CR rate
-mOS 11.2 months
www.nature.com/articles/s41...
-72% composite CR rate
-mOS 11.2 months
www.nature.com/articles/s41...
Reposted by Yogesh Jeelall
Stand up with ASH and #Fight4Hematology! 🩸💪
As executive orders threaten hematologic research and care of patients, ASH has created a new #Fight4Hematology Action Hub to keep you informed and involved.
Learn how to protect #hematology: www.hematology.org/a...
#HemeSky #MedSky
As executive orders threaten hematologic research and care of patients, ASH has created a new #Fight4Hematology Action Hub to keep you informed and involved.
Learn how to protect #hematology: www.hematology.org/a...
#HemeSky #MedSky
April 3, 2025 at 8:38 PM
Stand up with ASH and #Fight4Hematology! 🩸💪
As executive orders threaten hematologic research and care of patients, ASH has created a new #Fight4Hematology Action Hub to keep you informed and involved.
Learn how to protect #hematology: www.hematology.org/a...
#HemeSky #MedSky
As executive orders threaten hematologic research and care of patients, ASH has created a new #Fight4Hematology Action Hub to keep you informed and involved.
Learn how to protect #hematology: www.hematology.org/a...
#HemeSky #MedSky
Reposted by Yogesh Jeelall
Delighted to have our Perturb-multiome paper, led by #JorgeMartinRufino and @hemagene.bsky.social from our lab, published today in @science.org. Please check out this powerful approach to decipher gene regulatory networks enriched for genetic variation: www.science.org/doi/10.1126/...
Transcription factor networks disproportionately enrich for heritability of blood cell phenotypes
Most phenotype-associated genetic variants map to noncoding regulatory regions of the human genome, but their mechanisms remain elusive in most cases. We developed a highly efficient strategy, Perturb...
www.science.org
April 3, 2025 at 11:57 PM
Delighted to have our Perturb-multiome paper, led by #JorgeMartinRufino and @hemagene.bsky.social from our lab, published today in @science.org. Please check out this powerful approach to decipher gene regulatory networks enriched for genetic variation: www.science.org/doi/10.1126/...
Reposted by Yogesh Jeelall
Adapting systems biology to address the complexity of human disease in the single-cell era go.nature.com/3XBo6Vh #Review by @davidsebfischer.bsky.social, Martin A. Villanueva, Peter S. Winter & Alex K. Shalek @broadinstitute.org @mitofficial.bsky.social @ragoninstitute.bsky.social
Adapting systems biology to address the complexity of human disease in the single-cell era - Nature Reviews Genetics
Differences between humans and experimental models create a translational gap that makes it difficult to extrapolate research findings. The authors review systems-focused approaches to identify and co...
go.nature.com
March 11, 2025 at 9:05 AM
Adapting systems biology to address the complexity of human disease in the single-cell era go.nature.com/3XBo6Vh #Review by @davidsebfischer.bsky.social, Martin A. Villanueva, Peter S. Winter & Alex K. Shalek @broadinstitute.org @mitofficial.bsky.social @ragoninstitute.bsky.social
Reposted by Yogesh Jeelall
check out our study on outcomes in patients with CBF-AML treated with intensive chemotherapy regimens!
pubmed.ncbi.nlm.nih.gov/39157611/
pubmed.ncbi.nlm.nih.gov/39157611/
Real-world outcomes of intensive induction approaches in core binding factor acute myeloid leukemia - PubMed
Core-binding factor acute myeloid leukemia (CBF-AML) is characterized by the presence of inv(16)/t(16;16) or t(8;21) and is classified as a favorable risk by the 2022 European LeukemiaNet (ELN) guidel...
pubmed.ncbi.nlm.nih.gov
March 11, 2025 at 7:53 PM
check out our study on outcomes in patients with CBF-AML treated with intensive chemotherapy regimens!
pubmed.ncbi.nlm.nih.gov/39157611/
pubmed.ncbi.nlm.nih.gov/39157611/
Reposted by Yogesh Jeelall
had a great time discussing gemtuzumab ozogamicin in AML with the WolverHeme crew (@berninini.bsky.social & Anthony Perissinotti) and my friend/colleague Charlie Foucar!
creators.spotify.com/pod/show/wol...
creators.spotify.com/pod/show/wol...
LFGooo! The Rise, the Fall, and the Resurrection of Gemtuzumab in AML by WolverHeme Happy Hour
In this episode, Bernie and Anthony are joined by Dr. Charlie Foucar and Dr. Anand Patel to review the interesting and controversy-filled saga of gemtuzumab in AML? Should we be using this agent in AM...
creators.spotify.com
March 11, 2025 at 7:50 PM
had a great time discussing gemtuzumab ozogamicin in AML with the WolverHeme crew (@berninini.bsky.social & Anthony Perissinotti) and my friend/colleague Charlie Foucar!
creators.spotify.com/pod/show/wol...
creators.spotify.com/pod/show/wol...
Reposted by Yogesh Jeelall
Abelacimab significantly reduced bleeding events in atrial fibrillation patients compared to rivaroxaban, prompting early trial termination.
by Ruff CT, Patel SM (...) Sabatine MS et 16 al. in N Engl J Med #MedSky
📖 read the article: https://www.nejm.org/doi/10.1056/NEJMoa2406674
by Ruff CT, Patel SM (...) Sabatine MS et 16 al. in N Engl J Med #MedSky
📖 read the article: https://www.nejm.org/doi/10.1056/NEJMoa2406674
February 1, 2025 at 4:30 PM
Abelacimab significantly reduced bleeding events in atrial fibrillation patients compared to rivaroxaban, prompting early trial termination.
by Ruff CT, Patel SM (...) Sabatine MS et 16 al. in N Engl J Med #MedSky
📖 read the article: https://www.nejm.org/doi/10.1056/NEJMoa2406674
by Ruff CT, Patel SM (...) Sabatine MS et 16 al. in N Engl J Med #MedSky
📖 read the article: https://www.nejm.org/doi/10.1056/NEJMoa2406674
Reposted by Yogesh Jeelall
It's an honor to be part of this lecture series to honor Casey's legacy.
Our mentor Casey Brown, apart from being an extraordinary scientist, was a brilliant teacher who loved everything genetics. In his honor, some of the world's leading experts came together to create the 'Casey Brown Lecture Series' on human genetics 1/ shorturl.at/eCm7S
Casey Brown Lecture Series - YouTube
shorturl.at
January 6, 2025 at 2:18 PM
It's an honor to be part of this lecture series to honor Casey's legacy.
Reposted by Yogesh Jeelall
A 64-year-old woman presented with a 5-month history of fatigue and a 2-week history of fever and cough, with lymphadenopathy and splenomegaly. A serum sample showed a broad, greenish buffy coat of cells. Read the full case details: nej.md/4gyfLcr
#MedSky
#MedSky
January 6, 2025 at 2:32 PM
A 64-year-old woman presented with a 5-month history of fatigue and a 2-week history of fever and cough, with lymphadenopathy and splenomegaly. A serum sample showed a broad, greenish buffy coat of cells. Read the full case details: nej.md/4gyfLcr
#MedSky
#MedSky
Reposted by Yogesh Jeelall
Learn which oral abstracts the Scientific Program co-chairs thought were Best of #ASH24! Stream the Best of ASH session on the virtual meeting platform. 💻
#ASHKudos Drs. Jennifer Trowbridge (@trowbridgelab.bsky.social) & Sant-Rayn Pasricha for a superb job!
#HemeSky #Bloodsky #Hematology
#ASHKudos Drs. Jennifer Trowbridge (@trowbridgelab.bsky.social) & Sant-Rayn Pasricha for a superb job!
#HemeSky #Bloodsky #Hematology
December 21, 2024 at 4:01 PM
Learn which oral abstracts the Scientific Program co-chairs thought were Best of #ASH24! Stream the Best of ASH session on the virtual meeting platform. 💻
#ASHKudos Drs. Jennifer Trowbridge (@trowbridgelab.bsky.social) & Sant-Rayn Pasricha for a superb job!
#HemeSky #Bloodsky #Hematology
#ASHKudos Drs. Jennifer Trowbridge (@trowbridgelab.bsky.social) & Sant-Rayn Pasricha for a superb job!
#HemeSky #Bloodsky #Hematology
Reposted by Yogesh Jeelall
Just before the holidays, here is the latest from the Oricchio lab. In collaboration with the hemato-oncology team, we established a new model to test therapies on lymphoma patient samples by preserving the tissue composition and architecture of the original tumors. www.nature.com/articles/s41...
Development of patient-derived lymphomoids with preserved tumor architecture for lymphoma therapy screening - Nature Communications
Choosing the most effective anti-cancer therapy is difficult due to the high degree of tumour cell and tumour microenvironment heterogeneity. Here, the authors develop a platform for the generation of...
www.nature.com
December 16, 2024 at 8:06 PM
Just before the holidays, here is the latest from the Oricchio lab. In collaboration with the hemato-oncology team, we established a new model to test therapies on lymphoma patient samples by preserving the tissue composition and architecture of the original tumors. www.nature.com/articles/s41...
Reposted by Yogesh Jeelall
Thrilled to share that our paper www.nature.com/articles/s41... is featured in a fantastic Nature News & Views piece by thomastueting.bsky.social! 🎉 Grateful for the spotlight on our research and its impact on understanding cancer immunology. www.nature.com/articles/d41... 👀👉 rdcu.be/d3cRz
A lipid made by tumour cells reprograms immune cells
Insights into how cancer cells become unresponsive to therapy.
www.nature.com
December 14, 2024 at 10:51 PM
Thrilled to share that our paper www.nature.com/articles/s41... is featured in a fantastic Nature News & Views piece by thomastueting.bsky.social! 🎉 Grateful for the spotlight on our research and its impact on understanding cancer immunology. www.nature.com/articles/d41... 👀👉 rdcu.be/d3cRz
Reposted by Yogesh Jeelall
This week in #Science #Immunology: Jan Petersen, Jamie Rossjohn, & colleagues have solved the #CrystalStructure of human #LAG3 – #HLADR1 – #peptide complex, a major target of #ImmuneCheckpoint #therapy!
Crystal structure of the human LAG-3–HLA-DR1–peptide complex
The structural basis of how the immune checkpoint molecule LAG-3 binds peptide HLA-II is resolved.
www.science.org
December 13, 2024 at 10:45 PM
This week in #Science #Immunology: Jan Petersen, Jamie Rossjohn, & colleagues have solved the #CrystalStructure of human #LAG3 – #HLADR1 – #peptide complex, a major target of #ImmuneCheckpoint #therapy!
Reposted by Yogesh Jeelall
This week in #ScienceImmunology: Germinal Center B cells require asparagine (Asn) #metabolism for their function. GC B cells can acquire exogenous Asn from their local environment, but when Asn is limited, they utilise the enzyme asparginine synthetase. @ajclarke.bsky.social @yfy1.bsky.social
Asparagine availability controls germinal center B cell homeostasis
Asparagine metabolism is a critical regulator of germinal center B cell function.
www.science.org
December 14, 2024 at 1:28 PM
This week in #ScienceImmunology: Germinal Center B cells require asparagine (Asn) #metabolism for their function. GC B cells can acquire exogenous Asn from their local environment, but when Asn is limited, they utilise the enzyme asparginine synthetase. @ajclarke.bsky.social @yfy1.bsky.social
Reposted by Yogesh Jeelall
Hey all you #ASH24 people.
You need to look at this new paper in @naturemethods.bsky.social by Heme extraordinaires Grant Rowe and the Bluesky-less #HojunLi.
A paper that looks at Blood & Time from @bloodandtime.bsky.social himself!
#scRNAseq
#bioinformatics
🧬 💻
www.nature.com/articles/s41...
You need to look at this new paper in @naturemethods.bsky.social by Heme extraordinaires Grant Rowe and the Bluesky-less #HojunLi.
A paper that looks at Blood & Time from @bloodandtime.bsky.social himself!
#scRNAseq
#bioinformatics
🧬 💻
www.nature.com/articles/s41...
The dynamics of hematopoiesis over the human lifespan - Nature Methods
This Resource presents an atlas classifying the age-related changes in human hematopoietic stem and progenitor cells from gestation through aging.
www.nature.com
December 8, 2024 at 12:53 PM
Hey all you #ASH24 people.
You need to look at this new paper in @naturemethods.bsky.social by Heme extraordinaires Grant Rowe and the Bluesky-less #HojunLi.
A paper that looks at Blood & Time from @bloodandtime.bsky.social himself!
#scRNAseq
#bioinformatics
🧬 💻
www.nature.com/articles/s41...
You need to look at this new paper in @naturemethods.bsky.social by Heme extraordinaires Grant Rowe and the Bluesky-less #HojunLi.
A paper that looks at Blood & Time from @bloodandtime.bsky.social himself!
#scRNAseq
#bioinformatics
🧬 💻
www.nature.com/articles/s41...
Reposted by Yogesh Jeelall
Hematologists & pathologists find these cells fascinating: ring sideroblasts.
While most commonly associated with #MDS or inherited genetic disorders like #XLSA or #MLASA, these cells can also result from ethanol or tuberculosis drugs - even hypothermia.
They have such an interesting history!/1
While most commonly associated with #MDS or inherited genetic disorders like #XLSA or #MLASA, these cells can also result from ethanol or tuberculosis drugs - even hypothermia.
They have such an interesting history!/1
November 22, 2024 at 9:38 PM